StreetInsider.com News Articles

Glaukos completes enrollment in U.S. pivotal study for MicroShunt

Mon, 27 Jul 2026 07:01:11 -0400

Glaukos Corporation (NYSE: GKOS) has completed patient enrollment in its U.S. 510(k) pivotal study evaluating the PRESERFLO MicroShunt, a glaucoma drainage device, in adult patients with primary open-angle glaucoma who had failed previous medical and surgical treatment.

The prospective, multi-center, single-arm clinical trial enrolled at least 110 patients across sites in the United States and Canada. Eligible patients had previously undergone unsuccessful incisional or cilioablative glaucoma surgery and had inadequately controlled intraocular pressure despite medication.

The study's primary effectiveness endpoint is a 20% or greater reduction in mean diurnal intraocular pressure from baseline at 12 months post-surgery, without an increase in the

Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt

Mon, 27 Jul 2026 07:00:00 -0400

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced the completion of patient enrollment in its U.S. 510(k) pivotal study evaluating the PRESERFLO™ MicroShunt in adult patients with primary open-angle glaucoma (POAG) who failed previous medical and surgical treatment.

The PRESERFLO MicroShunt is a novel, ab-externo glaucoma drainage device designed to lower intraocular pressure (IOP). Constructed from a proprietary, biocompatible material known as SIBS [poly(styrene-block-isobutylene-block-styrene)], the PRESERFLO MicroShunt is an 8.5 mm flexible drainage device featuring

Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt

Mon, 27 Jul 2026 07:00:00 -0400

Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt

Mon, 27 Jul 2026 07:00:00 -0400

Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt

Mon, 27 Jul 2026 07:00:00 -0400

Form 4 GLAUKOS Corp For: Jul 16 Filed by: Thurman Alex R.

Tue, 21 Jul 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260721/26795986.html

Form 4 GLAUKOS Corp For: Jul 16 Filed by: Thurman Alex R.

Tue, 21 Jul 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260721/26795986.html

Glaukos Corporation (GKOS) PT Raised to $175 at Stifel on Epioxa Growth Acceleration

Fri, 17 Jul 2026 06:57:28 -0400

Stifel analyst Thomas Stephan raised the price target on Glaukos Corporation (NYSE: GKOS) to $175.00 (from $170.00) while maintaining a Buy rating.

The analyst commented, "Our iDose diligence (n=61) suggests ~60% of iDose eyes have prior SLT (higher-than-expected) and ~60% of procedures are performed in combination with MIGS (manageable given iDose is likely opted for more often if “un-stacked” by LCDs).If the proposed LCDs are finalized and unchanged, our comprehensive iDose revenue build points to 2027 sales of ~$240M, ~$80M- $90M below consensus—yet we believe this type of shortfall can easily be more than offset by Epioxa upside (~1,500 additional eyes

Glaukos Corporation (GKOS) PT Raised to $175 at Stifel on Epioxa Growth Acceleration

Fri, 17 Jul 2026 06:57:28 -0400

Stifel analyst Thomas Stephan raised the price target on Glaukos Corporation (NYSE: GKOS) to $175.00 (from $170.00) while maintaining a Buy rating.

Form 144 GLAUKOS Corp Filed by: Thurman Alex R.

Thu, 16 Jul 2026 12:18:00 -0400

si-local-file:///var/storage/secattach/20260716/26778570.html

Form 144 GLAUKOS Corp Filed by: Thurman Alex R.

Thu, 16 Jul 2026 12:18:00 -0400

si-local-file:///var/storage/secattach/20260716/26778570.html

Glaukos Corporation (GKOS) PT Raised to $180 at Truist Securities

Thu, 16 Jul 2026 07:09:19 -0400

Truist Securities analyst Richard Newitter raised the price target on Glaukos Corporation (NYSE: GKOS) to $180.00 (from $160.00) while maintaining a Buy rating.

Form 4 GLAUKOS Corp For: Jul 09 Filed by: Thurman Alex R.

Mon, 13 Jul 2026 20:04:00 -0400

si-local-file:///var/storage/secattach/20260713/26763483.html

Form 4 GLAUKOS Corp For: Jul 09 Filed by: Thurman Alex R.

Mon, 13 Jul 2026 20:04:00 -0400

si-local-file:///var/storage/secattach/20260713/26763483.html

Form 144 GLAUKOS Corp Filed by: Thurman Alex R.

Thu, 09 Jul 2026 12:42:00 -0400

si-local-file:///var/storage/secattach/20260709/26752313.html

Form 144 GLAUKOS Corp Filed by: Thurman Alex R.

Thu, 09 Jul 2026 12:42:00 -0400

si-local-file:///var/storage/secattach/20260709/26752313.html

Form 4 GLAUKOS Corp For: Jul 06 Filed by: Thurman Alex R.

Wed, 08 Jul 2026 21:13:00 -0400

si-local-file:///var/storage/secattach/20260708/26748831.html

Form 4 GLAUKOS Corp For: Jul 06 Filed by: Thurman Alex R.

Wed, 08 Jul 2026 21:13:00 -0400

si-local-file:///var/storage/secattach/20260708/26748831.html

Form 4 GLAUKOS Corp For: Jul 01 Filed by: Navratil Tomas

Wed, 08 Jul 2026 20:54:00 -0400

si-local-file:///var/storage/secattach/20260708/26748806.html

Form 4 GLAUKOS Corp For: Jul 01 Filed by: Navratil Tomas

Wed, 08 Jul 2026 20:54:00 -0400

si-local-file:///var/storage/secattach/20260708/26748806.html

Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29

Wed, 08 Jul 2026 07:00:00 -0400

Conference Call and Webcast Scheduled for 1:30 p.m. PT

ALISO VIEJO, Calif.--(BUSINESS WIRE)--

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release second quarter 2026 financial results after the market close on Wednesday, July 29, 2026. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on July 29, 2026.

A link to the live webcast will be available on the company’s website at

Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29

Wed, 08 Jul 2026 07:00:00 -0400

Conference Call and Webcast Scheduled for 1:30 p.m. PT

ALISO VIEJO, Calif.--(BUSINESS WIRE)--

A link to the live webcast will be available on the company’s website at

Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29

Wed, 08 Jul 2026 07:00:00 -0400

Conference Call and Webcast Scheduled for 1:30 p.m. PT

ALISO VIEJO, Calif.--(BUSINESS WIRE)--

A link to the live webcast will be available on the company’s website at

Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29

Wed, 08 Jul 2026 07:00:00 -0400

Conference Call and Webcast Scheduled for 1:30 p.m. PT

ALISO VIEJO, Calif.--(BUSINESS WIRE)--

A link to the live webcast will be available on the company’s website at

Form 144 GLAUKOS Corp Filed by: Thurman Alex R.

Mon, 06 Jul 2026 11:46:00 -0400

si-local-file:///var/storage/secattach/20260706/26734276.html